title: [Markers of Fas-mediated apoptosis in primary open-angle glaucoma and opportunities of their pharmacological correction].
abstract: In order to assess the role of apoptosis in pathogenesis of primary open-angle glaucoma (POAG) apoptosis markers were studied in blood serum and tear fluid of patients with or suspected to have different stages glaucoma. To date the study of POAC pathogenesis goes along with search of possible ways of pharmacotherapy, neuroprotection is considered to be a promising option. Dynamics of sFas/Apo-1 and sFasL as the markers of Fas-mediated apoptosis was studied during treatment. We used nootropic citicoline as a neuroprotector. The markers were studied using enzyme immunoassay. The results show association of POAG onset and progression with interruption of Fas-mediated apoptosis, indicated by the level and proportion of sFas/Apo-1 and sFasL in tear fluid and in a less degree in blood serum. Characteristic features are detected in Fas/FasL system associated with glaucoma stage and correlating with some clinical and functional parameters (perimetry) that is important for understanding of POAG pathogenesis and for prognosis of disease course.
authors.forename: O S
authors.initials: OS
authors.lastname: Slepova
authors.forename: M A
authors.initials: MA
authors.lastname: Frolov
authors.forename: N S
authors.initials: NS
authors.lastname: Morozova
authors.forename: A M
authors.initials: AM
authors.lastname: Frolov
authors.forename: Dzh N
authors.initials: DN
authors.lastname: Lovpache
mesh_terms: D000368:Aged; D017209:Apoptosis / Q000187:drug effects*; D015415:Biomarkers; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage / Q000493:pharmacokinetics; D016903:Drug Monitoring / Q000379:methods; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein / Q000378:metabolism*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents; D018697:Nootropic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D011379:Prognosis; D044967:Serum / Q000378:metabolism; D013666:Tears / Q000378:metabolism; D016896:Treatment Outcome; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D053222:Fas Ligand Protein; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D019014:fas Receptor; D003566:Cytidine Diphosphate Choline